Package Leaflet: Information for the Patient
Risedronate Weekly Combix 35 mg Film-Coated Tablets EFG
Sodium Risedronate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet
This medicine belongs to a group of non-hormonal medicines called bisphosphonates, which are used for the treatment of bone diseases. It acts directly on bones, strengthening them and thus reducing the likelihood of fractures.
Bone is a living tissue. Old bone tissue in the skeleton is constantly being renewed and replaced by new bone tissue.
Postmenopausal osteoporosis occurs in women after menopause when bone begins to weaken, becoming more fragile and prone to fractures after a fall or twist.
Osteoporosis can also affect men due to various causes, including aging and/or low levels of male hormone, testosterone.
The most likely bone fractures are those of the vertebrae, hip, and wrist, although they can occur in any bone in the body. Osteoporosis-related fractures can also cause back pain, loss of height, and a curved back. Some patients with osteoporosis may not have symptoms and may not even know they have it.
What is Risedronate Weekly Combix used for
This medicine is indicated for the treatment of osteoporosis
Do not take Risedronate Weekly Combix
Warnings and precautions
Consult your doctor or pharmacist before starting to take Risedronate Weekly Combix:
Your doctor will advise you what to do if you take this medicine and have any of the above problems.
Children and adolescents
The use of sodium risedronate is not recommended in children and adolescents (under 18 years) due to insufficient data on its safety and efficacy.
Other medicines and Risedronate Weekly Combix
Medicines containing any of the following substances reduce the effect of sodium risedronate when taken at the same time:
Take these medicines at least 30 minutes after taking Risedronate Weekly Combix.
Inform your doctor or pharmacist that you are using, have recently used, or may need to use any other medicine.
Taking Risedronate Weekly Combix with food and drinks
It is very important that you do not take this medicine with food or drinks (other than plain water) because they can interfere. In particular, do not take this medicine at the same time as dairy products (such as milk) as they contain calcium (see section 2, "Other medicines and Risedronate Weekly Combix").
Take food and drinks (other than plain water) at least 30 minutes after taking this medicine.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Do not take this medicine if you may be pregnant, are pregnant, or plan to become pregnant (see section 2, "Do not take Risedronate Weekly Combix"). The potential risk associated with the use of sodium risedronate in pregnant women is unknown.
Do not take this medicine if you are breastfeeding (see section 2, "Do not take Risedronate Weekly Combix"). Sodium risedronate can only be used in postmenopausal women and men.
Consult your doctor or pharmacist before using any medicine.
Driving and using machines
It is unknown whether sodium risedronate affects the ability to drive and use machines.
Risedronate Weekly Combix contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per film-coated tablet; it is essentially "sodium-free".
Follow exactly the administration instructions of this medicine as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is:
One Risedronate Weekly Combix tablet (35 mg of sodium risedronate) once a week.
Choose the day of the week that best suits your schedule. Each week, take the sodium risedronate tablet on the chosen day.
To facilitate taking the tablet on the same day each week, there are boxes on the back of the package. Mark the day of the week you have chosen to take the sodium risedronate tablet. Also, write down the dates you will take the tablet.
When to take Risedronate Weekly Combix tablets
Take the Risedronate Weekly Combix tablet at least 30 minutes before the first food, drink of the day (except if this drink is plain water) or other medicine of the day.
How to take Risedronate Weekly Combix tablets
Your doctor will indicate whether you should take calcium and vitamin supplements if the amount you take in your diet is not sufficient.
Follow exactly the administration instructions of the medicine contained in this leaflet or as indicated by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist.
If you take more Risedronate Weekly Combix than you should
If you or someone else has accidentally taken more tablets of sodium risedronate than prescribed, drink a full glass of milk and consult a doctor.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service (telephone 91 562 04 20), indicating the medicine and the amount taken.
If you forget to take Risedronate Weekly Combix
If you have forgotten to take the tablet on the chosen day, take it on the day you remember. And take the next tablet the following week, on the day you normally take the tablet.
Do not take a double dose to make up for the forgotten dose.
If you stop taking Risedronate Weekly Combix
If you stop treatment, you may start to lose bone mass. Please consult your doctor before deciding to stop treatment.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking Risedronate Weekly Combix and consult a doctor immediatelyif you experience any of the following symptoms:
Tell your doctor immediatelyif you experience any of the following side effects:
Atypical fractures of the thigh bone (femur) can occur rarely, especially in patients undergoing prolonged treatment for osteoporosis. Inform your doctor if you notice pain, weakness, or discomfort in the thigh, hip, or groin, as these may be early symptoms of a possible femur fracture.
However, in clinical studies, the side effects observed were generally mild and did not cause the patient to stop treatment.
Common side effects(may affect up to 1 in 10 patients):
Uncommon side effects(may affect up to 1 in 100 patients)
Rare side effects(may affect up to 1 in 1,000 patients)
During post-marketing use, the following side effects have been reported:
Rarely, at the start of treatment, a slight decrease in phosphate and calcium blood levels has been observed in some patients.
These changes are usually small and do not cause symptoms.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: http://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date is the last day of the month indicated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return the packaging and any unused medicine to the pharmacy. If you have any doubts, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Risedronate Weekly Combix
Core of the tablet:microcrystalline cellulose, crospovidone A, anhydrous colloidal silica, povidone, sodium stearyl fumarate, and magnesium stearate.
Coating of the tablet:hypromellose, macrogol, polysorbate 80, titanium dioxide (E171), yellow iron oxide (E172), and red iron oxide (E172).
Appearance of the product and contents of the pack
Risedronate Weekly Combix 35 mg film-coated tablets are round, bisected, biconvex, orange tablets with the inscription "35" on one face and smooth on the other. The tablets are presented in blisters, in boxes of 4 tablets.
Marketing authorization holder
Laboratorios Combix, S.L.U.
C/ Badajoz 2, Edificio 2
28223 Pozuelo de Alarcón (Madrid)
Spain
Manufacturer
Zydus France
ZAC Les Hautes Patures
Parc d'activités des Peupliers
25 Rue des Peupliers
92000 Nanterre
France
or
Centre Spécialités Pharmaceutiques
ZAC des Suzots
35 rue de la Chapelle
63450 Saint Amant Tallende
France
or
Netpharmalab Consulting Services S.L.
Carretera de Fuencarral 22
28108 Alcobendas, Madrid
Spain
or
Pharmex Advanced Laboratories S.L.
Ctra. A-431 Km. 19
14720 Almodóvar del Río (Córdoba)
Spain
Date of the last revision of this leaflet: May 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of RISEDRONATE WEEKLY COMBIX 35 mg FILM-COATED TABLETS in October, 2025 is around 19.84 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.